{"entity":{"id":"vnx-201","kind":"drug","name":"VNX-201","aka":[],"tldr":"VNX-201 is an experimental in vivo gene therapy from Vironexis Biotherapeutics, in preclinical development for GD2-positive neuroblastoma.","summary":"VNX-201 is an in vivo gene therapy (TransJoin vectorised T-cell engager) from Vironexis Biotherapeutics. A TransJoin vectorised T-cell engager programme against GD2 for neuroblastoma. Its furthest stage is preclinical development, for GD2-positive neuroblastoma. No clinical trial naming it is registered on ClinicalTrials.gov. Company milestone: '2026-Q1 IND enabling studies available'. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Vironexis Biotherapeutics: vironexis.com","url":"https://vironexis.com"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["gd2"],"drugs":[],"companies":["vironexis-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"VNX-201","modality":"In vivo gene therapy (TransJoin vectorised T-cell engager)","mechanism":"A TransJoin vectorised T-cell engager programme against GD2 for neuroblastoma.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vnx-201/","neighbours":{"target":[{"id":"gd2","kind":"target","name":"GD2 (disialoganglioside)","route":"/targets/gd2/"}],"company":[{"id":"vironexis-biotherapeutics","kind":"company","name":"Vironexis Biotherapeutics","route":"/companies/vironexis-biotherapeutics/"}]}}